Ojala, Olivia
Kuja-Halkola, Ralf
Bjureberg, Johan
Ohlis, Anna
Cederlöf, Martin
Norén Selinus, Eva
Lichtenstein, Paul
Larsson, Henrik
Lundström, Sebastian
Hellner, Clara
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 5 May 2022
Accepted: 13 October 2022
First Online: 3 November 2022
Change Date: 21 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12888-023-05338-y
Declarations
:
: Written informed consent was given by caregiver(s) at age 9/12 and by caregiver(s) and adolescent at age 15. The project has ethical approval issued by the ethical review board by the Swedish Ethical Review Authority or its predecessors (registration numbers for CATSS: 02–289 and 04-113, and DOGSS: 03–672 and 2010/1356-31/1). All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. The other authors have none to declare.